OPKO Health Stock

OPKO Health PEG

PEG Ratio (Price/Earnings-to-Growth) of OPKO Health (OPK) as of Aug 9, 2026.

PEG

0.00

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of OPKO Health is 2026 0.00 . PEG Ratio (Price/Earnings-to-Growth) of OPKO Health was 2025 -0.27 . It decreases by % higher compared to the previous year.
Access this data via the Eulerpool API

OPKO Health Stock analysis

What does OPKO Health do? OPKO Health Inc is an American company specializing in diagnostics, biopharmaceuticals, and pharmaceutical products. It was founded in 1991 by Dr. Phillip Frost, who still serves as CEO. The company is headquartered in Miami, Florida, and employs around 6,000 people worldwide. In recent years, OPKO Health Inc has undergone strong expansion, particularly through several acquisitions of other companies. These include Bio-Reference Laboratories, Inc., a leading provider of diagnostic services, and EirGen Pharma, a European company specializing in the production of high-quality pharmaceuticals. The business model of OPKO Health Inc is based on the development and marketing of products and services in the field of diagnostics and medical research. The company operates numerous state-of-the-art laboratories worldwide, which conduct diagnostic tests, genetic analyses, and medical research. OPKO Health Inc offers a wide range of products and services distributed across multiple business areas. One important area is the diagnostics division, which offers a wide range of tests and services, including cancer diagnostics, blood tests, genetic analyses, and clinical trials. Another important business area of OPKO Health Inc is the biopharmaceutical division, which focuses on the development and marketing of innovative therapies and medical products. The company develops medications against cancer and other diseases, as well as vaccines and immunological therapies. A third important business area of OPKO Health Inc is the pharmaceutical products division, which specializes in the production and distribution of pharmaceutical products and generic medications. The company has a broad portfolio of products, ranging from over-the-counter painkillers to medications for rare diseases. One of OPKO Health Inc's key products is the 4Kscore test, a blood test for diagnosing prostate cancer. This test is approved in the US and Europe and has a high accuracy rate in detecting aggressive forms of cancer. Another important product of the company is Rayaldee-Tabs, an innovative vitamin D medication used for the treatment of patients with chronic kidney disease (CKD). The medication has shown high efficacy in clinical studies and is currently approved in the US and Europe. OPKO Health Inc has become a significant player in the field of medical research and diagnostics through strong expansion and numerous acquisitions in recent years. The company focuses on high quality and innovative technologies to best support its customers worldwide. OPKO Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OPKO Health stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) OPKO Health since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s OPKO Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — OPKO Health

All Key Metrics — OPKO Health